Sign up to save your podcasts
Or
Share ReCode Therapeutics Lands $80M in Series A
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
ReCode Therapeutics Lands $80M in Series A
ReCode Therapeutics Lands $80M in Series A Back to HomeDALLAS, TX, ReCode Therapeutics has closed an oversubscribed $80M Series A financing round.
ReCode Therapeutics ("ReCode") ("theCompany"), a private biopharmaceutical company pioneering precision medicines for pulmonarydiseases, today announced the close of an oversubscribed $80 million Series A financing round.
"Our preclinical studies demonstrate that our targeted RNA therapies have great potential for thetreatment of life-threatening pulmonary diseases," commented David Lockhart, Ph.D., CEO andpresident, ReCode Therapeutics.
Along with the financing, ReCode has appointed a new board of directors.
About ReCode TherapeuticsReCode Therapeutics is a biopharmaceutical company developing precision medicines for geneticrespiratory diseases with significant unmet medical need. | To read full story, visit https://startuparound.com/read/1585411206.7678695/ReCode-Therapeutics-Lands-$80M-in-Series-A?ref=audio_experience
View all episodes
By Startup AroundReCode Therapeutics Lands $80M in Series A Back to HomeDALLAS, TX, ReCode Therapeutics has closed an oversubscribed $80M Series A financing round.
ReCode Therapeutics ("ReCode") ("theCompany"), a private biopharmaceutical company pioneering precision medicines for pulmonarydiseases, today announced the close of an oversubscribed $80 million Series A financing round.
"Our preclinical studies demonstrate that our targeted RNA therapies have great potential for thetreatment of life-threatening pulmonary diseases," commented David Lockhart, Ph.D., CEO andpresident, ReCode Therapeutics.
Along with the financing, ReCode has appointed a new board of directors.
About ReCode TherapeuticsReCode Therapeutics is a biopharmaceutical company developing precision medicines for geneticrespiratory diseases with significant unmet medical need. | To read full story, visit https://startuparound.com/read/1585411206.7678695/ReCode-Therapeutics-Lands-$80M-in-Series-A?ref=audio_experience